PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

This adverse event was reported 14 times

These drugs are most commonly taken by patients reporting PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS:

# Drug Count
0 URSODIOL 3
1 URSOSIOL 3
2 AZITHROMYCIN 2
3 AZITHROMYCIN DIHYDRATE 2
4 AZITHROMYCIN MONOHYDRATE 2
5 ODEVIXIBAT 2
6 TACROLIMUS 2
7 TACROLIMUS EXTENDED-RELEASE CAPSULES 2
8 TACROLIMUS OINTMENT 0.1% 2
9 CHOLESTYRAMINE 1
See all common drugs associated with PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ODEVIXIBAT 2 0.0050
1 MARALIXIBAT CHLORIDE 1 0.0010
2 GLATIRAMER ACETATE INJECTION 1 0.0002
3 URSOSIOL 3 0.0002
4 URSODIOL 3 0.0001
5 PHYTONADIONE 1 0.0001
6 CHOLESTYRAMINE 1 0.0001
7 TEDUGLUTIDE 1 0.0001
8 EVEROLIMUS TABLETS 1 0.0001
9 AZITHROMYCIN MONOHYDRATE 2 0.0000
See all drugs enriched for association with PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Ileal Bile Acid Transporter Inhibitor [EPC] 2 0.0044
1 Bile Acid [EPC] 3 0.0001
2 Vitamin K [EPC] 1 0.0001
3 Bile Acid Sequestrant [EPC] 1 0.0001
4 GLP-2 Analog [EPC] 1 0.0001
5 Provitamin D2 Compound [EPC] 1 0.0000
6 Interferon beta [EPC] 1 0.0000
7 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
8 Vitamin C [EPC] 1 0.0000
9 Kinase Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS